| US 7,507,540 B1 | ||
| Catalytic anti-factor VIII allo-antibodies | ||
| Srinivas Kaveri, Malakoff (France); Sébastien Lacroix-Desmazes, Ville D'Avray (France); and Michel Kazatchkine, Paris (France) | ||
| Assigned to Institut National de la Sante et de la Recherche Medicale (INSERM), Paris (France); and Bayer Pharma, Puteaux (France) | ||
| Appl. No. 10/31,938 PCT Filed Jul. 18, 2000, PCT No. PCT/EP00/06870 § 371(c)(1), (2), (4) Date Jul. 22, 2002, PCT Pub. No. WO01/07918, PCT Pub. Date Feb. 01, 2001. |
||
| Claims priority of application No. 99401841 (EP), filed on Jul. 21, 1999. | ||
| Int. Cl. G01N 33/53 (2006.01); C12P 21/04 (2006.01); A61K 35/14 (2006.01); C12N 5/06 (2006.01); C12N 9/00 (2006.01) | ||
| U.S. Cl. 435—7.1 [435/69.6; 435/7.7; 435/325; 435/326; 435/188.5; 530/383] | 25 Claims |
| 1. A method of determining the presence of anti-Factor VIII allow-antibodies capable of degrading Factor VIII in a mammal,
which comprises:
i) isolating the plasma from a sample of blood taken from said mammal,
ii) isolating anti-Factor VIII allo-antibodies from said plasma;
iii) placing said anti-Factor VIII allo-antibodies in contact with Factor VIII for a period of time sufficient to permit any
degradation of said Factor VIII by said anti-Factor VIII allo-antibodies; and
iv) determining, after said period of time, whether said Factor VIII has been degraded by said anti-Factor VIII allo-antibodies.
|